Gainers

• SELLAS Life Sciences Gr (NASDAQ:SLS) stock moved upwards by 20.5% to $6.29 during Tuesday's after-market session. The market value of their outstanding shares is at $968.7 million. As per the news, the Q1 earnings report came out today.
• Regenxbio (NASDAQ:RGNX) shares increased by 10.64% to $11.33. The company's market cap stands at $520.3 million.
• Akari Therapeutics (NASDAQ:AKTX) shares increased by 9.8% to $3.36. The company's market cap stands at $184.0 million.
• MaxCyte (NASDAQ:MXCT) shares moved upwards by 9.63% to $0.9. The company's market cap stands at $87.5 million. As per the press release, Q1 earnings came out today.
• Tevogen Bio Holdings (NASDAQ:TVGN) stock rose 8.56% to $7.57. The market value of their outstanding shares is at $28.3 million.
• SenesTech (NASDAQ:SNES) stock increased by 8.55% to $1.8. The company's market cap stands at $9.1 million. The company's, Q1 earnings came out today.

Losers

• Sunshine Biopharma (NASDAQ:SBFM) stock decreased by 21.0% to $0.83 during Tuesday's after-market session. The market value of their outstanding shares is at $5.0 million.
• WORK Medical Tech Gr (NASDAQ:WOK) shares fell 16.23% to $5.58.
• TriSalus Life Sciences (NASDAQ:TLSI) shares declined by 10.67% to $4.07. The company's market cap stands at $278.3 million. As per the press release, Q1 earnings came out today.
• China Pharma Holding (AMEX:CPHI) stock decreased by 10.37% to $0.8. The market value of their outstanding shares is at $2.6 million.
• OptimizeRx (NASDAQ:OPRX) shares decreased by 7.73% to $5.85. The market value of their outstanding shares is at $114.8 million. As per the press release, Q1 earnings came out today.
• TELA Bio (NASDAQ:TELA) shares declined by 6.86% to $0.95. The company's market cap stands at $43.4 million. As per the news, the Q1 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.